Pharmaceuticals News and Research

RSS

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Shire plc, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the Southern District of New York against Watson Pharmaceuticals, Inc. and its subsidiaries Watson Laboratories, Inc.-Florida, Watson Pharma, Inc., Andrx Corporation, and Andrx Pharmaceuticals, L.L.C. for infringement of Shire's U.S. Reissue Patent No. RE 41,148, U.S. Reissue Patent No. RE 42,096 and U.S. Patent No. 6,913,768 and also for breach of contract.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.

6 Apr 2011

Lack or loss of SIRT3 protein induces proliferation of breast cancer cells

Research published in the Cancer Cell journal in March was a significant step in knowing the causes of cancer better, especially breast cancer, revealing that the lack or loss of a protein in the cells known as SIRT3, induces the proliferation of this disease and thereby, this protein can be an may be a therapeutic target in the development of effective therapies for cancer. The research was led by Dra. Marcia Haigis of the Harvard Medical School, with the participation of Dr. Arkaitz Carracedo, from the Proteomics Laboratory at CIC bioGUNE.

6 Apr 2011

PQM program launches new public medicine database

In the growing global battle against substandard and counterfeit medicines, the Promoting the Quality of Medicines program has launched a new, public database of medicines collected and analyzed in collaboration with stakeholders from countries in Africa, South America and Southeast Asia.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Footstar acquires CPEX Pharmaceuticals

Footstar, Inc. today announced that certain of its subsidiaries have completed the previously announced acquisition of CPEX Pharmaceuticals, Inc., a specialty pharmaceutical company, in a transaction valued at approximately $76 million, plus fees and expenses relating to the transaction.

6 Apr 2011

Estrogen only hormone replacement not so risky after 50’s: Study

According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.

5 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Novavax, Inc. announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza. The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

5 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

5 Apr 2011

Angiotech's affected creditors unanimously approve Second Amended and Restated Plan of Compromise or Arrangement

Angiotech Pharmaceuticals, Inc. today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Artemisinin or high-pressure oxygen can boost natural cancer remedy

A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

Pharmaceuticals News and Research

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

Lack or loss of SIRT3 protein induces proliferation of breast cancer cells

PQM program launches new public medicine database

Merck enters definitive agreement to acquire Inspire

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Footstar acquires CPEX Pharmaceuticals

Estrogen only hormone replacement not so risky after 50’s: Study

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

La Jolla acquires GliaMed's novel class of compounds

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Aeterna Zentaris presents two posters on perifosine at AACR meeting

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

Angiotech's affected creditors unanimously approve Second Amended and Restated Plan of Compromise or Arrangement

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence